Work

Bon usage des antidépresseurs ISRS durant la grossesse – le défi de l’évaluation de la balance bénéfice-risque

Year: 2016

Type: article

Abstract: Studies report that between 6 and 13% of women experience symptoms of depression during pregnancy and the postpartum period. The abundant data available make selective serotonin reuptake inhibitors (SSRIs) the first line treatment in pregnancy when a pharmacological treatment is required. Risks associated with the use of SSRIs during pregnancy are limited (moderate effect size) and are often not distinguishable from those inherent to the mother's disease. Yet, several questions regarding the SSRI safety profile for the unborn child are still under debate or require additional epidemiological data. The decision of SSRI use during pregnancy needs an individual evaluation of the risk-benefit balance.

Source: JMIG

DOI: 10.53738/revmed.2016.12.510.0561

Authors: Etienne Weisskopf, Céline J. Fischer Fumeaux, Myriam Bickle Graz, Mathilde Morisod Harari, Manuella Epiney, Cristina Borradori Tolsa, Sylvie Rouiller, Jean-François Tolsa, Chin B. Eap, Yvan Vial, Chantal Csajka, Alice Panchaud

Language: French

Topic: Maternal Mental Health During Pregnancy and Postpartum

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W2527536877

FWCI: 0.607

Cites:

Cited by: 2

Related to: 10